Nouscom nhasi yakazivisa inokurudzira dhata nyowani yekushandura yakawanikwa kubva muyedzo yeChikamu 1 inoongorora NOUS-209. Iyo data yakaunzwa nezuro muchikamu cheKunonoka Kupwanya pa2022 American Association yeCancer Research (AACR) Musangano Wepagore.
NOUS-209, inotungamira chigadzirwa cheNouscom, ndeye-pasherufu yekudzivirira cancer yakanangana ne209 yakagovaniswa neoantigens. Iri kuferefetwa muChikamu 1 chekiriniki yekuedza, inopihwa pamwe chete neanti-PD-1 chekipoint inhibitor pembrolizumab, yekurapa Microsatellite Instable High (MSI-H) yemudumbu, colorectal uye gastro-esophageal junction solid tumors.
Yakambopa data yenguva pfupi yekiriniki yemusanganiswa (yakapihwa kuSosaiti yeImmunotherapy yeCancer's (SITC) Musangano Wepagore muna Mbudzi 2021) yakaratidza kuvimbisa zviratidzo zvekutanga zvekiriniki inoshanda muvarwere gumi nevaviri veMSI-H.
Iyo nyowani yekushandura data yakapihwa paAACR 2022 yakawedzera kutsigira zvakawanikwa uye yakaratidza NOUS-209 yakachengeteka, yakanyanya immunogenic ine zviratidzo zvinovimbisa zvekiriniki inoshanda. Zvakawanikwa zvakakosha zvaive zvinotevera:
• Vaccine immunogenicity yakaratidzwa neex-vivo IFN-ɣ ELISpot assay mu67% yevarwere vari padanho redose 1 (n=3), uye 100% (n=7) yevarwere vari padanho repiri.
• Muvarwere ve3 vane PRs yenguva refu avo pre / post kurapwa tumor biopsies yaive iripo, intratumoral TCR repertoire yakawedzerwa uye yakasarudzika post kurapwa neNOUS-209. Kuwedzera T effector memory post kurapwa kwakaonekwa.
• Mune mumwe wevarwere vatatu ava, vaccine-induced neoantigen chaiyo TCR yakarondwa kubva kunharaunda mune bundu biopsy post NOUS-209 kurapwa.
• Mibairo inoratidza kuti neoantigen chaiyo CD8+ T masero, anokonzerwa neNOUS-209, anowedzera uye anosiyana chete pakurapwa neNOUS-209, uye nokubudirira kupinza bundu microenvironment kuti aite anti-bundu chiitiko.
Marwan G. Fakih, MD, Medical Oncology Specialist paGuta reHope's Duarte California, uye muongorori weChidzidzo akati: “Kunyange zvazvo takaona kufambira mberi mukurapa kweMSI-High yakasimba mamota mumakore achangopfuura, kuchine chidikanwi chikuru chisina kuzadzikiswa. Saka zvinokurudzira zvikuru kuona iyi dhata itsva yeshanduro yeChikamu 1 inoratidza nzira iyo NOUS-209 inoita kuti masero eT awedzere uye kusiyanisa kweTCR muvarwere vanoratidza mhinduro dzekiriniki dzakasimba. Ndinotarisira zvikuru kuongororwa kuzere kwemhedzisiro yeChikamu 1 uye nekumwe kuvandudzwa kwekiriniki. "
Dr. Elisa Scarselli, Chief Scientific Officer uye Co-Muvambi weNouscom, akati: "Iyo data, yakawanikwa kubva kuvarwere ve12 metastatic MSI-H, inosimbisa siginecha yakafanana yakacherechedzwa mushure mekudzivirira muvarwere vane mhinduro yakasimba yekiriniki. Siginicha inoratidzwa nekuwedzera kweTCR repertoire uye kusiyanisa mune bundu rinopinza lymphocytes rinokurudzirwa nejekiseni neNOUS-209, pamwe nekuwedzera kwakafanana kweT masero ane effector memory phenotype. Zvakare, isu takakwanisa kuronda vaccine yakakonzeresa T masero pakati peaya akawedzerwa mushure mekurapa mubundu remumwe wevarwere ava.
"Tinotarisira kuvaka pane yedu inomanikidza yehumbowo-ye-chirevo data nekusimudzira zvakakosha zvidzidzo kubva muyedzo irikuenderera mberi kutsigira kuvandudzwa kweNOUS-209 seyangangoita yekutanga neoantigen kubva pasherufu yekudzivirira kenza yakanangana neMSI-H tumors."
ZVOKUBVA MUNYAYA INO:
- It is being investigated in a Phase 1 clinical trial, administered in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab, for the treatment of Microsatellite Instable High (MSI-H) gastric, colorectal and gastro-esophageal junction solid tumors.
- The signature is characterized by the TCR repertoire expansion and diversification in tumor infiltrating lymphocytes stimulated by vaccination with NOUS-209, together with a parallel increase of T cells with effector memory phenotype.
- Yakambopa data yenguva pfupi yekiriniki yemusanganiswa (yakapihwa kuSosaiti yeImmunotherapy yeCancer's (SITC) Musangano Wepagore muna Mbudzi 2021) yakaratidza kuvimbisa zviratidzo zvekutanga zvekiriniki inoshanda muvarwere gumi nevaviri veMSI-H.
